Ocugen is a clinical-stage biotechnology company developing gene therapies for major blindness and inherited retinal diseases. Its modifier gene therapy platform—led by candidates such as OCU400 for retinitis pigmentosa—aims to address many genetic mutations with a single approach rather than gene-by-gene replacement. The pipeline targets conditions with limited or no approved treatments, serving patients and partners focused on vision preservation and restoration.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 1.4 | — | -14.7 | — |
| Q3 2025 | 1.8 | — | -20.1 | — |
| Q4 2025 | -0.2 | — | -17.7 | — |
| Q1 2026 | 1.5 | — | -19.2 | — |
| Q2 2026 | 1.5 | 8.4% | -24.9 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Clinuvel Pharmaceuticals Limited (CUVL), Drugs Made In America Acquisition Corp. (DMAA), Neighborhood Intelligence, Inc. (NXH), Reading International, Inc. (RDIB), Oaktree Acquisition Corp. III Life Sciences (OACC), Lantronix, Inc. (LTRX)